Josep Maria Piulats
Institut Catala d'Oncologia (ICO) Hospitalet · ICO L´Hospitalet · ICO Hospitalet
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Josep Maria Piulats as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:14 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07057596 · Neoadjuvant Tebentafusp in Patients With Metastatic Uveal MelanomaGrupo Español Multidisciplinar de Melanoma · recruiting · Mestastatic Uveal Melanoma · study chair
- Ph2NCT05542342 · Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.Grupo Español Multidisciplinar de Melanoma · completed · Uveal Melanoma With Liver Metastases · study chair
- Ph2NCT02626962 · Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal MelanomaGrupo Español Multidisciplinar de Melanoma · completed · Uveal Melanoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:14 UTC. The ranking covers the 200 most relevant of 30 PubMed records, and a shared surname and initials can bring in a namesake. All 30 on PubMed
- Abiraterone in metastatic prostate cancer without previous chemotherapy.N Engl J Med · 20132,334 citationsRCR 67.7
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.N Engl J Med · 2021769 citationsRCR 39.3
- 648 citationsRCR 18.9
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.J Clin Oncol · 2020632 citationsRCR 25.6
- Rucaparib or Physician's Choice in Metastatic Prostate Cancer.N Engl J Med · 2023384 citationsRCR 31.8
- 329 citationsRCR 13.5
- 306 citationsRCR 42.7
- Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.N Engl J Med · 2023264 citationsRCR 22.2
- Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629).J Clin Oncol · 2020258 citationsRCR 11.2
- 228 citationsRCR 13.9